title: Overview of cefdinir: pharmacokinetics, safety, and efficacy in the treatment of uncomplicated skin and skin structure infections.
abstract: Uncomplicated skin and skin structure infections commonly are caused by Staphylococcus aureus and Streptococcus pyogenes. Cefdinir, an extended spectrum, third-generation cephalosporin is a safe and effective means of treating skin infections caused by these organisms, as well as many gram-negative pathogens. This article summarizes the pharmacokinetics, dosing schedule, adverse event profile, and efficacy data for cefdinir in adult and pediatric, populations in the treatment of uncomplicated skin and skin structure infections.
authors.affiliation: Abbott Laboratories, Abbott Park, Illinois, USA.
authors.forename: María M
authors.initials: MM
authors.lastname: París
authors.forename: Karen J
authors.initials: KJ
authors.lastname: Devcich
mesh_terms: D000328:Adult; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D000077525:Cefdinir; D002511:Cephalosporins / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D002648:Child; D006801:Humans; D017192:Skin Diseases, Bacterial / Q000188:drug therapy*; D018461:Soft Tissue Infections / Q000188:drug therapy*
chemical_list: D000890:Anti-Infective Agents; D002511:Cephalosporins; D000077525:Cefdinir